PURPOSE: Effects of combining local irradiation and intratumoral (i.t.) administration of cisplatin (CDDP) in a sustained-release drug delivery system (epi gel) were studied in a murine SCCVII squamous cell carcinoma model in mice. MATERIALS AND METHODS: The epinephrine injectable gel was used as a drug delivery system. Intratumoral pharmacokinetics of CDDP was studied by using 195mPt-CDDP. The tumor volume quadrupling time (TVQT) and tumor growth delay (TGD) time were used to evaluate the antitumor efficacy of treatment regimens. RESULTS: The concentration and residence of 195mPt-CDDP was significantly higher in tumors treated with 195mpt-CDDP/epi gel than in tumors treated with 195mPt CDDP gel or 195mPt-CDDP suspension. Intratumoral administration of CDDP/epi gel (4 mg/kg) produced an average TGD time of 15.5 +/- 2.8 days, which was 5.2 - 7.4 times longer than CDDP suspension i.t. or i.p. When combined with a single dose of radiation (10 Gy), i.t. administration of CDDP/epi gel was 2.0 - 3.6-fold as effective as administered i.t. in suspension (39.2 +/- 4.1 vs. 19.8 +/- 3.9 days of TGD, P < 0.05) or i.p. in solution (39.2 +/- 4.1 vs. 11.0 +/- 1.6 days, P < 0.001) in inhibiting tumor growth and produced 20-60% complete remission of tumors. When combined with fractionated irradiation, pre-irradiation CDDP administration was more effective than post-radiation administration (26.7 vs. 12.1 days of TGD, P < 0.05). Mice treated with CDDP/epi gel i.t. alone or in combination with irradiation, had little systemic toxicity. CONCLUSIONS: Intratumoral administration of CDDP using the sustained-release drug delivery system is an efficient and safe method to maximize the drug concentration in tumor, minimize the systemic toxicity and enhance antitumor efficacy of irradiation.
PURPOSE: Effects of combining local irradiation and intratumoral (i.t.) administration of cisplatin (CDDP) in a sustained-release drug delivery system (epi gel) were studied in a murine SCCVII squamous cell carcinoma model in mice. MATERIALS AND METHODS: The epinephrine injectable gel was used as a drug delivery system. Intratumoral pharmacokinetics of CDDP was studied by using 195mPt-CDDP. The tumor volume quadrupling time (TVQT) and tumor growth delay (TGD) time were used to evaluate the antitumor efficacy of treatment regimens. RESULTS: The concentration and residence of 195mPt-CDDP was significantly higher in tumors treated with 195mpt-CDDP/epi gel than in tumors treated with 195mPt CDDP gel or 195mPt-CDDP suspension. Intratumoral administration of CDDP/epi gel (4 mg/kg) produced an average TGD time of 15.5 +/- 2.8 days, which was 5.2 - 7.4 times longer than CDDP suspension i.t. or i.p. When combined with a single dose of radiation (10 Gy), i.t. administration of CDDP/epi gel was 2.0 - 3.6-fold as effective as administered i.t. in suspension (39.2 +/- 4.1 vs. 19.8 +/- 3.9 days of TGD, P < 0.05) or i.p. in solution (39.2 +/- 4.1 vs. 11.0 +/- 1.6 days, P < 0.001) in inhibiting tumor growth and produced 20-60% complete remission of tumors. When combined with fractionated irradiation, pre-irradiation CDDP administration was more effective than post-radiation administration (26.7 vs. 12.1 days of TGD, P < 0.05). Mice treated with CDDP/epi gel i.t. alone or in combination with irradiation, had little systemic toxicity. CONCLUSIONS: Intratumoral administration of CDDP using the sustained-release drug delivery system is an efficient and safe method to maximize the drug concentration in tumor, minimize the systemic toxicity and enhance antitumor efficacy of irradiation.
Authors: Walter Hundt; Esther L Yuh; Mykhaylo Burbelko; Andreas Kiessling; Mark D Bednarski; Silke Steinbach Journal: Eur Arch Otorhinolaryngol Date: 2011-10-15 Impact factor: 2.503
Authors: David Hu; Ontario D Lau; Linda Wang; Guanyu Wang; Dorthe Schaue; Li Zhu; Min Huang; Yuan Lin; Miranda Dennis; Elliot Abemayor; David A Elashoff; Steven M Dubinett; William H McBride; Sherven Sharma; Ben Wu; Maie A St John Journal: Arch Otolaryngol Head Neck Surg Date: 2012-04
Authors: Sarath Kanekal; Jayne Joo; Michael Bublik; Adir Bababeygy; Christopher Loh; Dan J Castro; Joel A Sercarz; Marcos B Paiva Journal: Eur Arch Otorhinolaryngol Date: 2008-07-08 Impact factor: 2.503
Authors: Yu-Hsuan Chu; Martha Sibrian-Vazquez; Jorge O Escobedo; Amanda R Phillips; D Thomas Dickey; Qi Wang; Martina Ralle; Peter S Steyger; Robert M Strongin Journal: Mol Pharm Date: 2016-06-24 Impact factor: 4.939
Authors: Yuan Lin; Jie Luo; Weichao Eric Zhu; Minu Srivastava; Dorthe Schaue; David A Elashoff; Steven M Dubinett; Sherven Sharma; Benjamin Wu; Maie A St John Journal: Otolaryngol Head Neck Surg Date: 2014-05-13 Impact factor: 3.497
Authors: Jonah A Kaplan; Rong Liu; Jonathan D Freedman; Robert Padera; John Schwartz; Yolonda L Colson; Mark W Grinstaff Journal: Biomaterials Date: 2015-10-27 Impact factor: 12.479